ABBOTT LABORATORIES

Listed Company

ABTCIK 0000001800NYSELarge AcceleratedPharmaceutical PreparationsIllinoisFY ends Dec 31

Period

FY 2025

Revenue

$44.33B

Net Income

$6.52B

Total Assets

$86.71B

Equity

$52.13B

Shares Out

1.74B

Op. Cash Flow

$9.57B

ABT$100.66−16.45% · past yearDBEQ Basic

Daily closing prices

Business

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of healthcare products worldwide. The company operates four reportable segments: Established Pharmaceutical Products (branded generic drugs sold primarily in emerging markets), Diagnostic Products (laboratory and point-of-care testing systems), Nutritional Products (infant formula and adult nutritional beverages), and Medical Devices (cardiovascular, diabetes care, and neuromodulation devices). Products are distributed through direct sales to wholesalers, hospitals, retailers, and consumers, as well as through third-party distributors across global markets.

Summary from 10-K filed 2026-02-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Sales	44,328	41,950	40,109	43,653	43,075
Cost of products sold, excluding amortization of intangible assets	19,319	18,706	17,975	19,142	18,537
Amortization of intangible assets	1,682	1,878	1,966	2,013	2,047
Research and development	2,942	2,844	2,741	2,888	2,742
Selling, general and administrative	12,332	11,697	10,949	11,248	11,324
Total Operating Cost and Expenses	36,275	35,125	33,631	35,291	34,650
Operating Earnings	8,053	6,825	6,478	8,362	8,425
Interest expense	493	559	637	558	—
Interest income	−308	−344	−385	−183	−43
Net foreign exchange (gain) loss	−50	−27	41	2	1
Other (income) expense, net	−548	−376	−479	−321	−277
Earnings before Taxes	8,466	7,013	6,664	8,306	8,211
Taxes on Earnings	1,942	−6,389	941	1,373	1,140
Net Earnings	6,524	13,402	5,723	6,933	7,071
Basic Earnings Per Common Share (in dollars per share)	3.73	7.67	3.28	3.94	3.97
Diluted Earnings Per Common Share (in dollars per share)	3.72	7.64	3.26	3.91	3.94
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,741	1,740	1,740	1,753	1,775
Dilutive Common Stock Options (in shares)	7	8	9	11	14
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,748	1,748	1,749	1,764	1,789
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	1	7	5	3	0

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	8,522	7,616	6,896	9,882	9,799
Investments, primarily bank time deposits and U.S. treasury bills	417	351	383	288	450
Trade receivables, less allowances of 2025: $490; 2024: $439	7,929	6,925	6,565	6,218	6,487
Finished products	3,976	3,700	3,946	3,805	3,081
Work in process	904	840	807	680	694
Materials	1,608	1,654	1,817	1,688	1,382
Total inventories	6,488	6,194	6,570	6,173	5,157
Other prepaid expenses and receivables	2,640	2,570	2,256	2,663	2,346
Total current assets	25,996	23,656	22,670	25,224	24,239
Investments	918	886	799	766	816
Land	541	528	529	511	525
Buildings	4,543	4,207	4,161	4,053	4,007
Equipment	17,571	15,517	15,179	14,164	13,528
Construction in progress	2,567	2,488	2,064	1,484	1,304
Property and equipment, at cost	25,222	22,740	21,933	20,212	19,364
Less: accumulated depreciation and amortization	13,406	12,082	11,779	11,050	10,405
Net property and equipment	11,816	10,658	10,154	9,162	8,959
Intangible assets, net of amortization	5,526	6,647	8,815	10,454	12,739
Goodwill	24,000	23,100	23,700	22,800	23,200
Deferred income taxes and other assets	18,422	16,459	7,097	6,033	5,212
Total Assets	86,713	81,414	73,214	74,438	75,196
Trade accounts payable	4,240	4,195	4,295	4,607	4,408
Salaries, wages, and commissions	1,745	1,701	1,597	1,556	1,625
Other accrued liabilities	5,812	5,143	5,422	5,845	5,181
Dividends payable	1,097	1,024	955	887	831
Income taxes payable	569	594	492	343	306
Current portion of long-term debt	3,033	1,500	1,080	2,251	754
Total current liabilities	16,496	14,157	13,841	15,489	13,105
Long-term debt	9,896	12,625	13,599	14,522	17,296
Post-employment obligations and other long-term liabilities	7,550	6,731	6,947	7,522	8,771
Commitments and contingencies	—	—	—	—	—
Preferred shares, one dollar par value Authorized 1,000,000 shares, none issued	0	0	0	0	0
Common shares, without par value Authorized 2,400,000,000 shares Issued at stated capital amount Shares: 2025: 1,996,795,525; 2024: 1,991,472,630	25,527	25,153	24,869	24,709	24,470
Common shares held in treasury, at cost Shares: 2025: 260,196,074; 2024: 259,774,639	−17,177	−16,844	−15,981	−15,229	−11,822
Earnings employed in the business	49,781	47,261	37,554	35,257	31,528
Total Abbott Shareholders Investment	52,130	47,664	38,603	36,686	35,802
Noncontrolling interests in subsidiaries	641	237	224	219	222
Total Shareholders Investment	52,771	47,901	38,827	36,905	36,024
Total Liabilities and Shareholders' Investment	86,713	81,414	73,214	74,438	75,196

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1,434	1,340	1,277	1,254	1,491
Share-based compensation	664	673	644	685	640
Investing and financing losses, net	65	482	126	215	55
Trade receivables	−652	−691	−356	−68	−383
Inventories	195	−58	−232	−1,413	−456
Prepaid expenses and other assets	−1,295	−796	−542	−75	−312
Trade accounts payable and other liabilities	954	356	−760	420	1,288
Income taxes	−5	−8,028	−585	−383	−908
Net Cash From Operating Activities	9,566	8,558	7,261	9,581	10,533
Acquisitions of property and equipment	−2,171	−2,207	−2,202	−1,777	−1,885
Acquisitions of businesses and technologies, net of cash acquired	−105	0	−877	0	−187
Proceeds from business dispositions	0	1	40	48	134
Purchases of investment securities	−167	−169	−159	−185	−173
Proceeds from sales of investment securities	3	28	43	152	77
Other	18	9	22	22	26
Net Cash From (Used in) Investing Activities	−2,422	−2,338	−3,133	−1,740	−2,008
Proceeds from issuance of (repayments of) short-term debt, net and other	−115	−100	21	47	−204
Proceeds from issuance of long-term debt and debt with maturities over 3 months	5	223	2	7	4
Repayments of long-term debt and debt with maturities over 3 months	−1,504	−660	−2,498	−753	−48
Purchases of common shares	−893	−1,295	−1,227	−3,795	−2,299
Proceeds from stock options exercised	396	264	167	167	255
Dividends paid	−4,116	−3,836	−3,556	−3,309	−3,202
Other	−82	0	0	0	0
Net Cash From (Used in) Financing Activities	−6,309	−5,404	−7,091	−7,636	−5,494
Effect of exchange rate changes on cash and cash equivalents	71	−96	−23	−122	−70
Net Increase (Decrease) in Cash and Cash Equivalents	906	720	−2,986	83	2,961
Income taxes paid	1,933	1,723	1,475	1,864	1,941
Interest paid	545	604	662	563	544

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ABBOTT LABORATORIES's CIK number?

ABBOTT LABORATORIES's SEC CIK number is 0000001800 (1800). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ABBOTT LABORATORIES's SEC filings?

All of ABBOTT LABORATORIES's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ABBOTT LABORATORIES last report earnings?

ABBOTT LABORATORIES (ABT) most recently filed an earnings 8-K with the SEC on Jul 16, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-048377). This is ABBOTT LABORATORIES's most recent earnings filing of record — not a forecast of its next earnings date.

What is ABBOTT LABORATORIES's most recent earnings 8-K?

ABBOTT LABORATORIES's latest earnings 8-K (Item 2.02) was filed Jul 16, 2026 under accession 0001628280-26-048377. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ABBOTT LABORATORIES's latest earnings 8-K →
Look up any company's CIK number →